Masroor Mirza, Mir Rashid, Javid Jamsheed, Prasant Y, Imtiyaz A, Mariyam Z, Mohan Anant, Ray P C, Saxena Alpana
Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India E-mail :
Asian Pac J Cancer Prev. 2015;16(15):6445-9. doi: 10.7314/apjcp.2015.16.15.6445.
NSCLC is a disease involving uncontrolled cell growth, which could result in metastases into nearby tissues beyond the lungs.
The aim of the present study was to analyze the influence of epidermal growth factor receptor (EGFR) gene expression on metastasis and survival in NSCLC patients. The present case-control study included 100 cases of NSCLC patients and 100 age and sex matched controls. EGFR gene expression was analyzed by quantitative real time PCR using serum RNA. Association with NSCLC patient survival was analyzed by the Kaplan-Meier method.
We analyzed EGFR gene expression and observed mean increased gene expression of 13.5 fold in NSCLC patients. Values reflected overall survival of patients with a median of 15.8 months in the cases of <13 fold increased gene expression vs 6.7 months with >13 fold increased EGFR gene expression (p=0.005). Distant metastatic patients with <13 fold increased EGFR gene expression had 7.9 months of median survival time while>13 fold increased EGFR gene expression had only 5 months of median survival time (p=0.03). Non metastatic patients with <13 fold increased EGFR gene expression had 18 months of median survival time as compared to only 7.1 months with >13 fold increased expression.
Higher cell free EGFR mRNA expression may play an important role in causing distant metastases and reducing overall survival of NSCLC patients in the Indian population.
非小细胞肺癌是一种涉及细胞生长失控的疾病,可导致癌细胞转移至肺外附近组织。
本研究旨在分析表皮生长因子受体(EGFR)基因表达对非小细胞肺癌患者转移和生存的影响。本病例对照研究纳入了100例非小细胞肺癌患者以及100例年龄和性别匹配的对照。使用血清RNA通过定量实时PCR分析EGFR基因表达。采用Kaplan-Meier法分析与非小细胞肺癌患者生存的相关性。
我们分析了EGFR基因表达,观察到非小细胞肺癌患者的基因表达平均增加了13.5倍。数值反映了基因表达增加<13倍的患者总体生存中位数为15.8个月,而EGFR基因表达增加>13倍的患者为6.7个月(p = 0.005)。EGFR基因表达增加<13倍的远处转移患者中位生存时间为7.9个月,而EGFR基因表达增加>13倍的患者中位生存时间仅为5个月(p = 0.03)。EGFR基因表达增加<13倍的非转移患者中位生存时间为18个月,而表达增加>13倍的患者仅为7.1个月。
在印度人群中,较高的游离EGFR mRNA表达可能在导致非小细胞肺癌患者远处转移和降低总体生存率方面发挥重要作用。